The goal of this study was to determine the ability of the major copper influx transporter CTR1 to mediate the cellular accumulation of cisplatin (DDP), carboplatin (CBDCA) and oxaliplatin (L-OHP). Wild type murine embryonic fibroblasts (CTR1 +/+ ) and a subline in which both alleles of CTR1 were deleted (CTR1 -/-) were tested for their ability to accumulate Pt when exposed to increasing concentrations of DDP, CBDCA or L-OHP for 1 h. They were also tested for their sensitivity to the growth inhibitory effect of each drug. Pt content was measured by ion- OHP is not dependent on CTR1 at higher concentrations. We conclude that L-OHP is a substrate for some other cellular entry mechanism, a feature consistent with its different clinical spectrum of activity.
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INTRODUCTION
Cisplatin (DDP), carboplatin (CBDCA) and oxaliplatin (L-OHP) are important chemotherapeutic agents, but the development of resistance during therapy is a common occurrence for all three. Several mechanisms that can contribute to resistance have previously been identified (Siddik, 2003) ; however, the molecular mechanisms are not well-defined. While the development of resistance is thought to be multifactoral, the most commonly identified defect is decreased drug accumulation (reviewed in Gately and Howell, 1993) ). The reasons for decreased accumulation are unknown due in part to the fact that the pathways by which these platinum-containing drugs enter and exit from cells are poorly defined. The platinum drugs enter cells much more slowly than most other classes of small molecule anticancer agents; current evidence suggests that one component of their uptake is mediated by a transporter or channel (Gately and Howell, 1993) . Many other metal ions enter cells on specific transporters, and acquisition of resistance to DDP is often accompanied by resistance to other metalloids (Naredi et al., 1995; Romach et al., 2000; Tobey and Tesmer, 1985) . In particular, cells selected for resistance to DDP are often cross-resistant to copper (Cu) and vice versa (Katano et al., 2002; Safaei et al., 2004b) . Recent studies from this and other laboratories have demonstrated that both Cu efflux transporters, ATP7A and ATP7B, modulate the export of DDP Samimi et al., 2004a) .
Copper transporter 1 (CTR1) is the major Cu influx transporter. Deletion of the yCTR1 gene in S. cerevisiase markedly reduces the accumulation of all 3 clinically available Ptcontaining chemotherapeutic agents as well as the DDP analog AM0473 (Ishida et al., 2002; Lin et al., 2002) . A preliminary study suggested that the cellular accumulation of DDP was also impaired in embryonic fibroblasts established from mice in which both mCTR1 alleles had been This article has not been copyedited and formatted. The final version may differ from this version. (Ishida et al., 2002) . Forced over-expression of hCTR1 in human ovarian carcinoma cells enhanced DDP uptake (Holzer et al., 2003) . Increased hCTR1 expression in human small cell lung cancer cells (Song et al., 2004) was reported to enhance the uptake of DDP, CBDCA and L-OHP but over-expression of hCTR1 in human squamous carcinoma cells was reported to have no effect on DDP uptake (Beretta et al., 2004) . Such forced over-expression of hCTR1 is toxic to human cells, and it is not clear that CTR1 functions normally at such high intracellular levels as evidenced by the finding that increased CTR1 expression and DDP uptake into the whole cell is accompanied by minimal change in sensitivity to the cytotoxic effect of the drug and DNA adduct formation (Holzer et al., 2004) .
The amino acid sequence of murine CTR1 shares 92 % homology with human CTR1 (Kuo et al., 2001) . While deletion of both mCTR1 alleles produced embryonic lethality, CTR1 +/+ and CTR1 -/-embryo fibroblast cell lines were successfully established from the parental and knockout mice (Lee et al., 2001) . In order to refine understanding of how CTR1 modulates the cellular pharmacology of the Pt-containing drugs, we carried out further investigations using this isogenic pair of mouse embryo fibroblasts. We report here quantitative studies of the effect of loss of mCTR1 function on cellular accumulation of the 3 clinically utilized Pt-containing drugs and on sensitivity to the cytotoxic effects of these agents. The results indicate that CTR1
regulates the cellular accumulation of all 3 drugs at concentrations attainable in humans but that at 5-fold higher concentrations, while accumulation of DDP and CBDCA is still CTR1-dependent, L-OHP accumulation becomes CTR1-independent indicating that it is a substrate for another cell entry mechanism.
This article has not been copyedited and formatted. The final version may differ from this version. Cell lines. The murine embryonic fibroblasts, originally isolated from day 7 embryos and immortalized using SV40 large T antigen, were cultured as described previously . Cells were grown in 20% fetal bovine serum, 2 mM glutamine, 1X non-essential amino acids, 55 µM 2-mercaptoethanol, 50 mg/L uridine and 110 mg/ml pyruvate.
Measurement of 64 Cu accumulation.
Cu uptake measurements were made using cell cultures that were 80% confluent in the 30 mm wells of a 6-well plate. Following addition of prewarmed media containing 2 µM 64 CuSO 4 the plates were incubated at 37º C in 5% CO 2 for 30 min. At the end of the incubation period the plates were placed on ice and the wells were rinsed 3 times with 3 ml ice cold PBS. Cell lysis buffer (0.1 % Triton-X, 1 % SDS in phosphate buffered saline) in a volume of 500 µL was added to the wells, and the lysate was harvested by scraping the dish twice before it was transferred to tubes for γ counting on a Beckman Gamma 5500B. Six cultures were harvested for each data point. Lysates from a set of identical cultures not exposed to 64 CuSO 4 were used to measure protein concentration.
Pt accumulation assays. Cells were plated in 6-well plates in media without any drugs.
Once the cultures were 80 % confluent, 2 or 10 µM DDP, 2, 10 or 12 µM CBDCA or 2, 6 or 10 µM L-OHP was added and plates were incubated at 37º C in 5% CO 2 for 1 h. The plates were then placed on ice and wells were rinsed 3 times with 3 ml ice cold phosphate buffered saline.
Cells were harvested by dissolving them in 70% nitric acid at 65ºC for at least 2 hours. Samples were diluted to 5% nitric acid with water containing 1 ppb indium and 0.1% Triton-X. Pt content was determined using inductively-coupled plasmon mass spectroscopy (ICP-MS) (Element2;
Perkin Elmer Life Sciences) on an instrument available through the Analytical Facility at the Scripps Institute of Oceanography. Lysates from a set of identical cultures suspended in 0.1%
Triton-X and 1% SDS in phosphate buffered saline were used to measure protein concentration. . As shown in Table 1 that were found to be equitoxic to human ovarian carcinoma cells in clonogenic assays performed in an earlier study . The equitoxic concentrations of the drugs were 2 µM for DDP, 12 µM for CBDCA and 6 µM for L-OHP. This resulted data on the accumulation in CTR1 +/+ and CTR1 -/-cells being available for 2 concentrations of DDP and 3 concentrations for CBDCA and L-OHP. As shown in Table 1 This article has not been copyedited and formatted. The final version may differ from this version. (Holzer et al., 2004; Song et al., 2004; Beretta et al., 2004) . As previously reported , the accumulation of Cu in the CTR1 -/-cells was found to be markedly reduced in the CTR1 -/-cells when they were exposed to low concentrations of Cu for 1 h. Accumulation in the CTR1 -/-cells was just 5.7% of that in the CTR1 +/+ cells. Loss of CTR1 function had a smaller but still substantial effect on the uptake of all 3 Pt-containing drugs when cells were exposed to 2 µM drug. At this concentration accumulation was ∼36% of that in the wild type cells. In the case of DDP and CBDCA this deficit in accumulation was still evident when cells were exposed to a 5-fold higher concentration; however, in the case of L-OHP the deficit produced by loss of CTR1 disappeared at the higher concentration. This suggests that CTR1 contributes importantly to the cellular uptake of all 3 drugs at the low concentrations typically attained in patient plasma whereas at higher concentrations L-OHP enters the cell predominantly via another mechanism.
Drug sensitivity assay
S. cerevisiae express two high affinity Cu influx transporters, yCTR1 and yCTR3 (Petris, 2004) . Knockout of yCTR1 in yeast in which yCTR3 was disabled reduced the accumulation of DDP, CBCDA and L-OHP similar to the results obtained with the CTR1 +/+ and CTR1 -/-mouse embryo fibroblasts (Ishida et al., 2002; Lin et al., 2002) . Thus, despite the fact that yCTR1 contains 8 N-terminal Cu binding motifs while mCTR1 contains only 2, both transporters appear to function similarly with respect to Pt drug accumulation.
This article has not been copyedited and formatted. The final version may differ from this version. In the mammalian cells, there was an association between the extent to which Pt drug uptake was impaired in the CTR1 -/-cells and the extent to which sensitivity to the growth inhibitory effect of the drug was reduced. The loss of CTR1 had a greater effect on the potency of DDP than CBDCA, but inspection of the curves in Figure 1 indicates that even at very high drug concentrations CTR1 was still important to the growth inhibitory effect of these drugs. This suggests that other routes of entry for DDP and CBDCA into the cell do not become dominant over CTR1 even at high drug concentrations. In contrast, loss of CTR1 had less effect on the growth inhibitory potency of L-OHP consistent with the observation that the concentration required to inhibit growth was already above that at which the deficit in accumulation produced by loss of CTR1 had disappeared.
The fact that deletion of CTR1 did not completely eliminate DDP and CBDCA accumulation indicates that CTR1 is not the only route by which these drugs enter mammalian cells. This mirrors the situation for Cu; even though loss of CTR1 reduced Cu uptake by 94%, and this transporter is essential for embryonic viability, Cu nevertheless enters the cell in amounts sufficient to sustain growth. To date, no other transporter has definitively been shown to mediate the influx of Cu in mammalian cells . Likewise, loss of CTR1 function reduced DDP and CBDCA uptake to only 36% of control, indicating that there is yet another mechanism by which DDP and CBDCA enter cells that has not yet been characterized.
The results of this study provide strong evidence that, at low concentrations, CTR1
mediates cellular accumulation of all 3 Pt-containing drugs currently used in patients, but that L-OHP differs from DDP and CBDCA in that its dependence on CTR1 diminishes at higher CBDCA and L-OHP are shown in Figure 2 . L-OHP differs from DDP and CBDCA in that it contains a bulky diaminocyclohexane ring, a feature that appears to make it a substrate for a non-CTR1-dependent entry mechanism at higher concentrations. Given the exquisite specificity of CTR1 for Cu relative to other metal ions, it is surprising that any of these drugs are a substrate for the CTR1-mediated accumulation mechanism.
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